Methods for decreasing detrusor

• US 20050228049A1
• Filed: 05/24/2005
• Published: 10/13/2005
• Est. Priority Date: 12/20/2002
• Status: Abandoned Application

• Current Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Original Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Inventors: Thor, Karl Bruce, Fraser, Matthew Oliver, Burgard, Edward C.
• Application Number:
  US11/136,183
• Publication Number:
  US 20050228049A1
• Time in Patent Office: Days
• US Class Current: 514/561
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α₂δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the α₂δ calcium channel subunit.

Claims

1. A method for decreasing overactivity of the detrusor muscle, comprising administering to an individual in need thereof a therapeutically effective amount of an α

₂δ

subunit calcium channel modulator.

2. The method of claim 1, wherein said α

₂δ

subunit calcium channel modulator is administered on an as-needed basis.

4. The method of claim 1, wherein said α

₂δ

subunit calcium channel modulator is administered orally, transmucosally, sublingually, buccally, intranasally, transurethrally, rectally, by inhalation, topically, transdermally, parenterally, intrathecally, vaginally, or perivaginally.

5. The method of claim 1, wherein said α

₂δ

subunit calcium channel modulator is a GABA analog.

6. The method of claim 5, wherein said GABA analog is Gabapentin.

7. The method of claim 5, wherein said GABA analog is Pregabalin.

3. The method of 1, wherein said α

₂δ

subunit calcium channel modulator is administered prior to commencement of an activity wherein decreasing overactivity of the detrusor muscle would be desirable.

8. A method for decreasing detrusor instability, comprising administering to an individual in need thereof a therapeutically effective amount of an α

₂δ

subunit calcium channel modulator.

9. The method of claim 8, wherein said α

₂δ

subunit calcium channel modulator is administered on an as-needed basis.

11. The method of claim 8, wherein said α

₂δ

subunit calcium channel modulator is administered orally, transmucosally, sublingually, buccally, intranasally, transurethrally, rectally, by inhalation, topically, transdermally, parenterally, intrathecally, vaginally, or perivaginally.

12. The method of claim 8, wherein said α

₂δ

subunit calcium channel modulator is a GABA analog.

13. The method of claim 12, wherein said GABA analog is Gabapentin.

14. The method of claim 12, wherein said GABA analog is Pregabalin.

10. The method of 8, wherein said α

₂δ

subunit calcium channel modulator is administered prior to commencement of an activity wherein decreasing detrusor instability would be desirable.